Log in

Ovid Therapeutics Stock Forecast, Price & News

-0.01 (-0.37 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $2.68
50-Day Range
MA: $5.52
52-Week Range
Now: $2.68
Volume4.29 million shs
Average Volume1.05 million shs
Market Capitalization$170.01 million
P/E RatioN/A
Dividend YieldN/A
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop, manufacture and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was founded in 2014 and is headquartered in New York, New York.
Ovid Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:OVID



Sales & Book Value

Annual SalesN/A
Book Value$1.46 per share


Net Income$-60,460,000.00


Market Cap$170.01 million
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable
-0.01 (-0.37 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

How has Ovid Therapeutics' stock been impacted by COVID-19?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 0.0% and is now trading at $2.68.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Ovid Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ovid Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Ovid Therapeutics?

Wall Street analysts have given Ovid Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ovid Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Ovid Therapeutics

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its earnings results on Thursday, November, 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.07.
View Ovid Therapeutics' earnings history

What price target have analysts set for OVID?

9 Wall Street analysts have issued 1-year target prices for Ovid Therapeutics' stock. Their forecasts range from $4.00 to $40.00. On average, they anticipate Ovid Therapeutics' share price to reach $12.57 in the next year. This suggests a possible upside of 369.1% from the stock's current price.
View analysts' price targets for Ovid Therapeutics

Are investors shorting Ovid Therapeutics?

Ovid Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,050,000 shares, an increase of 15.1% from the October 31st total of 2,650,000 shares. Based on an average daily volume of 949,200 shares, the days-to-cover ratio is presently 3.2 days. Approximately 8.5% of the company's shares are sold short.
View Ovid Therapeutics' Short Interest

Who are some of Ovid Therapeutics' key competitors?

What other stocks do shareholders of Ovid Therapeutics own?

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:
  • Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir, Chairman & CEO (Age 67, Pay $821.32k)
  • Dr. Amit Rakhit, Pres & Chief Medical Officer (Age 50, Pay $694.05k)
  • Mr. Timothy G. Daly, Exec. VP of Fin., Treasurer & Corp. Controller (Age 49, Pay $439.45k)
  • Dr. Matthew J. During, Founder & Chairman of Scientific Advisory Board (Age 63)
  • Ms. Lora Pike, Sr. Director of Investor Relations & PR
  • Mr. Thomas Michael Perone J.D., M.B.A., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 55)
  • Ms. Suzanne K. Wakamoto SPHR, SHRM-SCP, Sr. VP of HR
  • Dr. Anna Kazanchyan, Sr. VP of Product Devel. (Age 51)
  • Dr. Dirk Haasner, Sr. VP of Manufacturing & CMC QA (Age 55)
  • Dr. Claude Nicaise, Head of Strategic Orphan Regulatory Affairs (Age 67)

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.83%), Vivo Capital LLC (2.19%), Sofinnova Investments Inc. (1.92%), State Street Corp (1.27%), AXA S.A. (1.04%) and Wells Fargo & Company MN (0.94%). Company insiders that own Ovid Therapeutics stock include Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends for Ovid Therapeutics

Which major investors are selling Ovid Therapeutics stock?

OVID stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., AXA S.A., Platinum Investment Management Ltd., Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, State Street Corp, JPMorgan Chase & Co., and Virtus ETF Advisers LLC.
View insider buying and selling activity for Ovid Therapeutics

Which major investors are buying Ovid Therapeutics stock?

OVID stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Sofinnova Investments Inc., Squarepoint Ops LLC, First Trust Advisors LP, Blair William & Co. IL, GSA Capital Partners LLP, OLD Mission Capital LLC, and AQR Capital Management LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Ovid Therapeutics

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $2.68.

How big of a company is Ovid Therapeutics?

Ovid Therapeutics has a market capitalization of $170.01 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 60 workers across the globe.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is www.ovidrx.com.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.